Skip to main content
. 2022 Mar 9;13:1225. doi: 10.1038/s41467-022-28844-1

Fig. 6. The enhancing effect of β-NMN on remyelination of the mice requires SIRT2.

Fig. 6

a Quantification of differentiated oligodendrocytes from P0 WT mice cultured for 48 h (n = 3). TM, Thiomyristoyl. b–e Images and quantification of proliferating OPCs (b, c) cultured for 36 h and differentiated oligodendrocytes (d, e) cultured for 48 h from P0 SIRT2−/− mice (n = 3). Scale bars, 50 μm. f Experiment design for testing the impact of β-NMN on OPC proliferation in vivo. g–j Images and quantification of oligodendrocyte lineage cells and proliferating OPCs within the demyelination lesions at 5 dpl (n = 5). Scale bar, 50 μm. k Experiment design for testing the impact of β-NMN on OPC differentiation in vivo. l–o Images and quantification of oligodendrocyte lineage cells and differentiated oligodendrocytes within the demyelination lesions at 10 dpl (n = 5). Scale bar, 50 μm. p Experiment design for testing the impact of β-NMN on remyelination efficiency in vivo at 21 dpl. q TEM micrographs within the lesions at 21 dpl. Scale bar, 1 μm. r–w Quantification of the proportion of myelin pathology level (r), remyelinated axons (s), G-Ratio average (t), individual G-Ratio distribution (u, linear regression) and distance between DL (v, w) within the lesions at 21 dpl (n = 5). All data are presented as mean ± SEM. The center, upper and lower line represent the median, upper and lower quartiles, respectively (w). *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed t-test (c, e) or one-way ANOVA followed by Tukey’s post hoc test (a, h–j, m–o, s, t, v, w) or two-way repeated ANOVA followed by Sidak’s post hoc test (r). In all instances ***p  <  0.001. n.s. no significance. In (a), **p = 0.004 (DMSO vs. DMSO + β-NMN), **p = 0.002 (DMSO + β-NMN vs. β-NMN + 5 μM TM); In (n), *p = 0.02 (WT + PBS vs. WT + β-NMN); In (o), *p = 0.05 (WT + PBS vs. WT + β-NMN); In (r), *p = 0.02 (grade 2, WT + PBS vs. WT + β-NMN).